Developing microbiome-directed therapeutics for treating childhood undernutrition
Developing microbiome-directed therapeutics for treating childhood undernutrition
Abstract
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
Learning objectives
This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.
- Understand evidence that impaired postnatal development of the gut microbiota is causally related to childhood undernutrition
- Understand how preclinical gnotobiotic animal models can be used to develop new microbiota-directed therapeutics
- Understand how multiomic methods, including SomaScan® Assay proteomics, can be used to judge the efficacy and mechanism of action of these therapeutics in clinical studies
Jeffrey Gordon, MD
Director, Edison Family Center for Genome Sciences and Systems Biology, Washington University
Michael J. Barratt, PhD
Executive Director, Center for Gut Microbiome and Nutrition Research, Washington University
Developing microbiome-directed therapeutics for treating childhood undernutrition
A webinar presented by Jeffrey Gordon, MD, and Michael J. Barratt, PhD
Request more information
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.